Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares gained 3.3% to $9.20. The company, on Feb. 14, presented final results from a Phase 1 study of CDX-301 (recombinant human Flt3L; rhuFlt3L) in healthy volunteers that strongly support the initiation of a pilot study in hematopoietic stem cell transplantation later this year. Share volume was 1.6 million, compared to an all-day average of 1.2 million